Iktos
Jean-Christophe Meillon has a strong background in the pharmaceutical industry. Jean-Christophe began their career in 2001 as a Research Scientist at Pierre Fabre. After a few months, they moved to Idenix Pharmaceuticals, where they worked as a Senior Research Scientist for nearly a decade.
In 2010, Jean-Christophe founded Oxeltis, where they served as the Medicinal Chemistry Director. Jean-Christophe'srole involved small-scale synthesis of APIs, with a specialty in Nucleoside and Carbohydrate chemistry. Jean-Christophe was also responsible for chemical problem-solving. Jean-Christophe held this position until December 2020.
Currently, Jean-Christophe is the Head of Robotics Lab at Iktos, a role they started in July 2022.
Jean-Christophe Meillon has an extensive education background in the field of organic chemistry. Jean-Christophe obtained their Bachelor's degree in Organic Chemistry from Université Paul Sabatier Toulouse III, where they attended from 1989 to 1990. Following this, they pursued a Ph.D. in Organic Chemistry at Université de Sherbrooke from 1994 to 1998. Lastly, they attended the University of Cambridge from 1998 to 2000, where they focused on Organic Chemistry, although no specific degree name is mentioned.
This person is not in any offices
Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.